– The scenario – often with ‘hospital superbugs’found – may also improve by a discovery by a research team at the University of British Columbia, in collaboration with UBC spin-off company Inimex Pharmaceuticals, a peptide that has been identified control the infection by increasing the body’s immune system. Now in danger now in danger because of the explosion in antibiotic – resistant bacteria, a third of all deaths on this planet are the result of infection, so there is an urgent need for new therapies to create, ‘says Robert Hancock, principal investigator and Canada Research Chair in in Pathogenomics and. ‘The advantage of this peptide is that it acts on the host to induce a protective immune response, and does not depend of bacteria act directly. This means it is unlikely to be resistant bacteria.

Published the discovery in animal models, in the journal Nature Biotechnology.The researchers tested the peptide activity against Staphylococcus aureus including MRSA, a superbug as vancomycin-resistant enterococci and Salmonella. In Staph and VRE infections, although bacteria were not completely eradicated, IDR-1 significantly reduced bacterial counts and mortality, when started as either 24-48 hours before or four hours after the infection. In Salmonella, the peptide provided significant protection prior to infection prior to infection setting in.The results revealed no clear correlation between of the indicators of bone turnover and alcohol use, the authors suggest that advantage on alcohol are not osteogenesis bone formation and absorption. Instead, they suggest that alcohol can improve micro-architecture of the bone.